Table 3.
Metabolic and lipid markers separated by group.
| Obese PCOS (n=36) | Obese controls (n=17) | p-value | |
|---|---|---|---|
| Hemoglobin A1c, % | 5.4 ± 0.3 | 5.4 ± 0.2 | 0.913 |
| C-peptide, ng/mL | 3.4 ± 0.9 | 2.5 ± 0.7 | 0.002 |
| Total cholesterol, mg/dL | 165 ± 32 | 154 ± 33 | 0.257 |
| Triglyceride, mg/dL | 126 ± 53 | 108 ± 50 | 0.249 |
| HDL-C, mg/dL | 36 ± 6 | 42 ± 9 | 0.040 |
| LDL-C, mg/dL | 115 ± 29 | 97 ± 26 | 0.044 |
| Apolipoprotein B, mg/dL | 95.13 ± 20.24 | 78.45 ± 17.10 | 0.019 |
| Fasting glucose, mg/dL | 85 ± 5 | 85 ± 5 | 0.950 |
| Glucose infusion rate, mg/kg/min | 5.24 ± 1.86 | 9.10 ± 2.69 | <0.0001 |
| Glucose infusion rate fat free mass, mg/lean kg/min | 9.76 ± 3.43 | 16.15 ± 4.33 | <0.0001 |
| Fasting free fatty acids, μmol/L | 630 ± 134 | 622 ± 1685 | 0.889 |
| 10 phase free fatty acids, μmol/L | 267 ± 148 | 143 ± 71 | 0.0004 |
| 80 phase free fatty acids, μmol/L | 62 ± 31 | 32 ± 14 | 0.001 |
| Fasting insulin, μIU/mL | 27 ± 12 | 20 ± 9 | 0.126 |
| 10 phase insulin, μIU/mL | 59 ± 23 | 42 ± 21 | 0.029 |
| 80 phase insulin, μIU/mL | 266 ± 55 | 209 ± 50 | 0.014 |
| Free fatty acid IC50, μIU/mL | 68 ± 28 | 41 ± 10 | 0.001 |
Continuous variables are presented as mean ± standard deviation.
A p-value in bold font indicates a significant difference between groups.
PCOS, polycystic ovarian syndrome; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; IC50, insulin concentration needed for 50% suppression from fasting free fatty acids concentration.